<DOC>
	<DOCNO>NCT00725452</DOCNO>
	<brief_summary>Prospective , open-label- , 1-arm , multicenter observational study determine dose interval Infliximab infusion subject plaque psoriasis .</brief_summary>
	<brief_title>Five-Year Observation Remicade Treatment Plaque Psoriasis Austria ( Study P04900 )</brief_title>
	<detailed_description>This study population choose non-probability sample .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>According European Summary Product Characteristics ( SPC ) : Adult subject moderatetosevere plaque psoriasis fail respond , contraindication , intolerant systematic therapy include cyclosporine , methotrexate , PsoralenultravioletA light ( PUVA ) . According European SPC : Subjects tuberculosis severe infection sepsis , abscess , opportunistic infection . Subjects moderatetosevere heart failure ( New York Heart Association ( NYHA ) class III/IV ) . Subjects history hypersensitivity Infliximab murine proteins excipients . Subjects elevate liver enzymes ( &gt; 5 upper limit normal ( ULN ) ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>